This study looks at how a mobile based app called 'Dose Check' used along with Tresiba helps to control blood sugar level in participants with type 2 diabetes mellitus. Participants will get Tresiba as prescribed by the study doctor or participants will continue already prescribed treatment with Tresiba. Participants will also be prescribed to use Dose Check app by the study doctor and will be asked to install the Dose Check app in their mobile phone, which will support participants with the correct dose of Tresiba. This study will last for about 6 to 7 months.
Study Type
OBSERVATIONAL
Enrollment
179
Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
Dr. Sulaiman Al Habib- Al Qassim
Buraidah, Al Qassim, Saudi Arabia
Almoosa Specialist Hospital
Ihsaa, Saudi Arabia
Saudi airlines Medical Services
Jeddah, Saudi Arabia
Saudi German Hospital
Jeddah, Saudi Arabia
My clinic
Jeddah, Saudi Arabia
Saudi German Hospital
Khamis Mushait, Saudi Arabia
Al Mowasat Khobar
Khobar, Saudi Arabia
Sulaiman Al Habib- Al Khobar
Khobar, Saudi Arabia
King Fahad Hospital of the University
Khobar, Saudi Arabia
Al Hammadi
Riyadh, Saudi Arabia
...and 4 more locations
Change in glycated haemoglobin (HbA1c)
Measured in percentage point.
Time frame: From baseline (week 0) to end of study visit(week 26 [-4 to +8 weeks])
Participants reaching individual HbA1c target set by physician
Measured as number of participants (yes/no).
Time frame: end of study visit (week 26 [-4 to +8 weeks])
Participants reaching physician set individual fasting blood glucose (FBG) target
Measured as number of participants (yes/no).
Time frame: From baseline (week 0) to end of study visit(week 26 [-4 to +8 weeks])
Time to physician set individual FBG target from first reported FBG
Measured in weeks.
Time frame: From baseline (week 0) to end of study visit(week 26 [-4 to +8 weeks])
Participants achieving target level FBG according to clinical guidance
Measured as number of participants (yes/no).
Time frame: From baseline (week 0) to end of study visit(week 26 [-4 to +8 weeks])
Change in laboratory measured FPG
Measured in milligrams per deciliter (mg/dL).
Time frame: From baseline (week 0) to end of study visit(week 26 [-4 to +8 weeks])
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.